Xtandi Gets Green Light From FDA for Nonmetastatic CRPC

The FDA approved the use of enzalutamide (Xtandi, Astellas) for patients with nonmetastatic castration-resistant prostate cancer, based on results from the phase 3 PROSPER trial.